BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 15093572)

  • 1. Treatment implications for radiation-induced nausea and vomiting in specific patient groups.
    Horiot JC; Aapro M
    Eur J Cancer; 2004 May; 40(7):979-87. PubMed ID: 15093572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylaxis versus treatment: is there a better way to manage radiotherapy-induced nausea and vomiting?
    Horiot JC
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(4):1018-25. PubMed ID: 15519770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimising antiemetic therapy: what are the problems and how can they be overcome?
    Aapro M
    Curr Med Res Opin; 2005 Jun; 21(6):885-97. PubMed ID: 15969889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy-induced emesis in elderly cancer patients: the role of 5-HT3-receptor antagonists in the first 24 hours.
    Aapro M; Johnson J
    Gerontology; 2005; 51(5):287-96. PubMed ID: 16110229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Croatian guideliness for prevention of chemotherapy induced nausea and vomiting].
    Tomek R; Vrdoljak E; Vrbanec D; Nemet D; Matković V; Plestina S; Gugić D; Dintinjana RD; Bolanca A; Samarzija M; Petković M
    Lijec Vjesn; 2009; 131(3-4):49-53. PubMed ID: 19514248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting.
    Herrstedt J
    Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of chemotherapy-induced nausea and vomiting in elderly cancer patients.
    Jakobsen JN; Herrstedt J
    Crit Rev Oncol Hematol; 2009 Sep; 71(3):214-21. PubMed ID: 19162507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granisetron in the control of radiotherapy-induced nausea and vomiting: a comparison with other antiemetic therapies.
    Feyer P; Seegenschmiedt MH; Steingraeber M
    Support Care Cancer; 2005 Sep; 13(9):671-8. PubMed ID: 16044252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: comparison between elderly and non-elderly patient response.
    Massa E; Astara G; Madeddu C; Dessì M; Loi C; Lepori S; Mantovani G
    Crit Rev Oncol Hematol; 2009 Apr; 70(1):83-91. PubMed ID: 18723369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting.
    Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA
    J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granisetron: an update on its clinical use in the management of nausea and vomiting.
    Aapro M
    Oncologist; 2004; 9(6):673-86. PubMed ID: 15561811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiotherapy-induced nausea and vomiting (RINV): antiemetic guidelines.
    Feyer PCh; Maranzano E; Molassiotis A; Clark-Snow RA; Roila F; Warr D; Olver I
    Support Care Cancer; 2005 Feb; 13(2):122-8. PubMed ID: 15592688
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5-HT3 receptor antagonists for prevention of late acute-onset emesis.
    Constenla M
    Ann Pharmacother; 2004 Oct; 38(10):1683-91. PubMed ID: 15316106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
    Grote T; Hajdenberg J; Cartmell A; Ferguson S; Ginkel A; Charu V
    J Support Oncol; 2006 Sep; 4(8):403-8. PubMed ID: 17004515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evolution of antiemetic studies for radiation-induced nausea and vomiting within an outpatient palliative radiotherapy clinic.
    McKenzie E; Chan D; Parsafar S; Razvi Y; McFarlane T; Rico V; Pasetka M; DeAngelis C; Chow E
    Support Care Cancer; 2019 Sep; 27(9):3245-3252. PubMed ID: 31119459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19).
    ; Wong RK; Paul N; Ding K; Whitehead M; Brundage M; Fyles A; Wilke D; Nabid A; Fortin A; Wilson D; McKenzie M; Ackerman I; Souhami L; Chabot P; Pater J
    J Clin Oncol; 2006 Jul; 24(21):3458-64. PubMed ID: 16849762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy-induced nausea and vomiting.
    Lohr L
    Cancer J; 2008; 14(2):85-93. PubMed ID: 18391612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Management of radiation-induced nausea and vomiting.
    Abdelsayed GG
    Exp Hematol; 2007 Apr; 35(4 Suppl 1):34-6. PubMed ID: 17379085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiotherapy-induced nausea and vomiting.
    Dennis K; Maranzano E; De Angelis C; Holden L; Wong S; Chow E
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):685-92. PubMed ID: 22098284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment.
    Jordan K; Kasper C; Schmoll HJ
    Eur J Cancer; 2005 Jan; 41(2):199-205. PubMed ID: 15661543
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.